Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free “GeneSwitch” vector
Authors:
- 1 November 2018
- journal article
- research article
- Published by Elsevier in Experimental Neurology
- Vol. 309, 79-90
Abstract
No abstract availableKeywords
Funding Information
- German Research Council
- Centre of Nanoscale Microscopy and Physiology of the Brain
- European Community (E!7900: ESTAR13113/19/NCBR/2014)
This publication has 46 references indexed in Scilit:
- Adeno-associated Virus-mediated, Mifepristone-regulated Transgene Expression in the BrainMolecular Therapy Nucleic Acids, 2013
- Striatal neuronal loss correlates with clinical motor impairment in Huntington's diseaseMovement Disorders, 2012
- Evaluation of an AAV2-Based Rapamycin-Regulated Glial Cell Line-Derived Neurotrophic Factor (GDNF) Expression Vector SystemPLOS ONE, 2011
- Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expressionHuman Molecular Genetics, 2010
- Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus MonkeysHuman Gene Therapy, 2009
- Statistical power analyses using G*Power 3.1: Tests for correlation and regression analysesBehavior Research Methods, 2009
- Nigrostriatal rAAV-mediated GDNF Overexpression Induces Robust Weight Loss in a Rat Model of Age-related ObesityMolecular Therapy, 2009
- Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD MiceThe Journal of Neuroscience, 2008
- Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington’s diseaseProceedings of the National Academy of Sciences, 2006
- Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changesExperimental Neurology, 2005